Non-alcoholic fatty liver disease in children: Focus on nutritional interventions

Nutrients

Volumn 6, Issue 11, 2014, Pages 4691-4705

  Yang, Min ^a   Gong, Sitang ^a   Ye, Shui Qing ^b   Lyman, Beth ^b   Geng, Lanlan ^a   Chen, Peiyu ^a   Li, Ding You ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Non alcoholic fatty liver disease (NAFLD); Nutrition

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN C3; BETA PARVIN; FRUCTOSE; GLUCOKINASE; ICOSAPENTAENOIC ACID; LIPID PHOSPHATE PHOSPHATASE RELATED PROTEIN TYPE 4; LYMPHOCYTE CYTOSOLIC PROTEIN 1; LYSOPHOSPHOLIPASE; LYSOPHOSPHOLIPASE LIKE 1; MEMBRANE PROTEIN; NEUROCAN; OMEGA 3 FATTY ACID; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 GENE; PEPTIDES AND PROTEINS; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTEIN PHOSPHATASE 1 REGULATORY SUBUNIT 3B; SOLUTE CARRIER FAMILY 38 MEMBER 8; SORTING AND ASSEMBLY MACHINERY COMPONENT; SQUALENE SYNTHASE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ARTICLE; BODY FAT; CHILDHOOD OBESITY; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; DIET THERAPY; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GLUCOSE METABOLISM; HUMAN; INTESTINE FLORA; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ADOLESCENT; ANIMAL; CHILD; DIET; DISEASE MODEL; LIFESTYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY; RISK FACTOR;

ADOLESCENT; ANIMALS; ANTIOXIDANTS; CHILD; DIET; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; FRUCTOSE; HUMANS; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; PREBIOTICS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WEIGHT LOSS;

EID: 84908267347     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6114691     Document Type: Article

References (68)

1. Flegal, K.M.; Carroll, M.D.; Kit, B.K.; Ogden, C.L. Prevalence of obesity and trends in the distribution of: Body mass index among US adults, 1999-2010. JAMA 2012, 307, 491-497.
2. Ogden, C.L.; Carroll, M.D.; Kit, B.K.; Flegal, K.M. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012, 307, 483-490.
3. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Abera, S.F, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384, 766-781.
4. Flegal, K.M.; Kit, B.K.; Orpana, H.; Graubard, B.I. Association of all-cause mortality with overweight andobesity using standard body mass index categories: A systematic review and meta-analysis. JAMA 2013, 309, 71-82.
5. Day, C.P. Non-alcoholic fatty liver disease: A massive problem. Clin. Med. 2011, 11, 176-178.
6. Vajro, P.; Lenta, S.; Socha, P.; Dhawan, A.; McKiernan, P.; Baumann, U.; Durmaz, O.; Lacaille, F.; McLin, V.; Nobili, V. Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 700-713.
7. Schwimmer, J.B.; Deutsch, R.; Kahen, T.; Lavine, J.E.; Stanley, C.; Behling, C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118, 1388-1393.
8. Wiegand, S.; Keller, K.M.; Röbl, M.; L’Allemand, D.; Reinehr, T.; Widhalm, K.; Holl, R.W. Obese boys at increased risk for nonalcoholic liver disease: Evaluation of 16,390 overweight or obese children and adolescents. Int. J. Obes. (Lond.) 2010, 34, 1468-1474.
9. Huang, S.C.; Yang, Y.J. Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level. J. Pediatr. Gastroenterol. Nutr. 2013, 56, 145-150.
10. Graham, R.C.; Burke, A.; Stettler, N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J. Pediatr. Gastroenterol. Nutr. 2009, 49, 442-449.
11. Fraser, A.; Longnecker, M.P.; Lawlor, D.A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007, 133, 1814-1820.
12. Romeo, S.; Kozlitina, J.; Xing, C.; Pertsemlidis, A.; Cox, D.; Pennacchio, L.A.; Boerwinkle, E.; Cohen, J.C.; Hobbs, H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40, 1461-1465.
13. Lin, Y.C.; Chang, P.F.; Chang, M.H.; Ni, Y.H. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am. J. Clin. Nutr. 2014, 99, 869-874.
14. Marzuillo, P.; del Giudice, E.M.; Santoro, N. Pediatric fatty liver disease: Role of ethnicity and genetics. World J. Gastroenterol. 2014, 20, 7347-7355.
15. Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836-1846.
16. Lomonaco, R.; Sunny, N.E.; Bril, F.; Cusi, K. Nonalcoholic fatty liver disease: Current issues and novel treatment approaches. Drugs 2013, 73, 1-14.
17. Jarrar, M.H.; Baranova, A.; Collantes, R.; Ranard, B.; Stepanova, M.; Bennett, C.; Fang, Y.; Elariny, H.; Goodman, Z.; Chandhoke, V, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 27, 412-421.
18. García-Ruiz, C.; Baulies, A.; Mari, M.; García-Rovés, P.M.; Fernandez-Checa, J.C. Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: Cause or consequence? Free Radic. Res. 2013, 47, 854-868.
19. Neuschwander-Tetri, B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52, 774-788.
20. Bechmann, L.P.; Kocabayoglu, P.; Sowa, J.P.; Sydor, S.; Best, J.; Schlattjan, M.; Beilfuss, A.; Schmitt, J.; Hannivoort, R.A.; Kilicarslan, A, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013, 57, 1394-1406.
21. Li, D.Y.; Yang, M.; Edwards, S.; Ye, S.Q. Non-alcoholic fatty liver disease: For better or worse, blame gut microbiota? JPEN J. Parenter. Enteral. Nutr. 2013, 37, 787-793.
22. Zhu, L.; Baker, S.S.; Gill, C.; Liu, W.; Alkhouri, R.; Baker, R.D.; Gill, S.R. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 2013, 57, 601-609.
23. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55, 2005-2023.
24. Saadeh, S.; Younossi, Z.M.; Remer, E.M.; Gramlich, T.; Ong, J.P.; Hurley, M.; Mullen, K.D.; Cooper, J.N.; Sheridan, M.J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123, 745-750.
25. Zelber-Sagi, S.; Ratziu, V.; Oren, R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World J. Gastroenterol. 2011, 17, 3377-3389.
26. Tilg, H.; Moschen, A. Weight loss: Cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol. Dietol. 2010, 56, 159-167.
27. Promrat, K.; Kleiner, D.E.; Niemeier, H.M.; Jackvony, E.; Kearns, M.; Wands, J.R.; Fava, J.L.; Wing, R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51, 121-129.
28. Nobili, V.; Manco, M.; Devito, R.; di Ciommo, V.; Comparcola, D.; Sartorelli, M.R.; Piemonte, F.; Marcellini, M.; Angulo, P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008, 48, 119-128.
29. Koot, B.G.; van derBaan-Slootweg, O.H.; Tamminga-Smeulders, C.L.; Rijcken, T.H.; Korevaar, J.C.; van Aalderen, W.M.; Jansen, P.L.; Benninga, M.A. Lifestyle intervention for non-alcoholic fatty liver disease: Prospective cohort study of its efficacy and factors related to improvement. Arch. Dis. Child. 2011, 96, 669-674.
30. Reinehr, T.; Schmidt, C.; Toschke, A.M.; Andler, W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch. Dis. Child. 2009, 94, 437-442.
31. Grønbæk, H.; Lange, A.; Birkebæk, N.H.; Holland-Fischer, P.; Solvig, J.; Hørlyck, A.; Kristensen, K.; Rittig, S.; Vilstrup, H. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 223-228.
32. Bray, G.A.; Popkin, B.M. Calorie-sweetened beverages and fructose: What have we learned 10 years later. Pediatr. Obes. 2013, 8, 242-248.
33. Caton, P.W.; Nayuni, N.K.; Khan, N.Q.; Wood, E.G.; Corde, R. Fructose induces gluconeogenesis and lipogenesis through a SIRT1-dependent mechanism. J. Endocrinol. 2011, 208, 273-283.
34. Lê, K.A.; Faeh, D.; Stettler, R.; Ith, M.; Kreis, R.; Vermathen, P.; Boesch, C.; Ravussin, E.; Tappy, L. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am. J. Clin. Nutr. 2006, 84, 1374-1379.
35. Lê, K.A.; Ith, M.; Kreis, R.; Faeh, D.; Bortolotti, M.; Tran, C.; Boesch, C.; Tappy, L. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am. J. Clin. Nutr. 2009, 89, 1760-1765.
36. Faeh, D.; Minehira, K.; Schwarz, J.M.; Periasamy, R.; Park, S.; Tappy, L. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 2005, 54, 1907-1913.
37. Silbernagel, G.; Machann, J.; Unmuth, S.; Schick, F.; Stefan, N.; Häring, H.U.; Fritsche, A. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: An exploratory trial. Br. J. Nutr. 2011, 106, 79-86.
38. Crescenzo, R.; Bianco, F.; Coppola, P.; Mazzoli, A.; Tussellino, M.; Carotenuto, R.; Liverini, G.; Iossa, S. Fructose supplementation worsens the deleterious effects of short-term high-fat feeding on hepatic steatosis and lipid metabolism in adult rats. Exp. Physiol. 2014, in press.
39. Sapp, V.; Gaffney, L.; EauClaire, S.F.; Matthews, R.P. Fructose leads to hepatic steatosis in zebrafish that is reversed by mTOR inhibition. Hepatology 2014, doi:10.1002/hep.27284.
40. Spruss, A.; Kanuri, G.; Wagnerberger, S.; Haub, S.; Bischoff, S.C.; Bergheim, I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50, 1094-1104.
41. Vos, M.B.; Lavine, J.E. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013, 57, 2525-2531.
42. Ouyang, X.; Cirillo, P.; Sautin, Y.; McCall, S.; Bruchette, J.L.; Diehl, A.M.; Johnson, R.J.; Abdelmalek, M.F. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 2008, 48, 993-999.
43. Thuy, S.; Ladurner, R.; Volynets, V.; Wagner, S.; Strahl, S.; Königsrainer, A.; Maier, K.P.; Bischoff, S.C.; Bergheim, I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J. Nutr. 2008, 138, 1452-1455.
44. Bergheim, I.; Weber, S.; Vos, M.; Krämer, S.; Volynets, V.; Kaserouni, S.; McClain, C.J.; Bischoff, S.C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J. Hepatol. 2008, 48, 983-992.
45. Assy, N.; Nasser, G.; Kamayse, I.; Nseir, W.; Beniashvili, Z.; Djibre, A.; Grosovski, M. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can. J. Gastroenterol. 2008, 22, 811-816.
46. Sullivan, J.S.; le, M.T.; Pan, Z.; Rivard, C.; Love-Osborne, K.; Robbins, K.; Johnson, R.J.; Sokol, R.J.; Sundaram, S.S. Oral fructose absorption in obese children with non-alcoholic fatty liver disease. Pediatr. Obes. 2014, doi:10.1111/ijpo.238.
47. Jin, R.; Welsh, J.A.; le, N.A.; Holzberg, J.; Sharma, P.; Martin, D.R.; Vos, M.B. Dietary Fructose Reduction Improves Markers of Cardiovascular Disease Risk in Hispanic-American Adolescents with NAFLD. Nutrients 2014, 6, 3187-3201.
48. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362, 1675-1685.
49. Lavine, J.E.; Schwimmer, J.B.; van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N., et al. Effect of vitamin E or metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial. JAMA 2011, 305, 1659-1668.
50. Sarkhy, A.A.; Al-Hussaini, A.A.; Nobili, V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi. J. Gastroenterol. 2014, 20, 143-153.
51. Capanni, M.; Calella, F.; Biagini, M.R.; Genise, S.; Raimondi, L.; Bedogni, G.; Svegliati-Baroni, G.; Sofi, F.; Milani, S.; Abbate, R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study. Aliment. Pharmacol. Ther. 2006, 23, 1143-1151.
52. Spadaro, L.; Magliocco, O.; Spampinato, D.; Piro, S.; Oliveri, C.; Alagona, C.; Papa, G.; Rabuazzo, A.M.; Purrello, F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 2008, 40, 194-199.
53. Scorletti, E.; Bhatia, L.; McCormick, K.G.; Clough, G.F.; Nash, K.; Hodson, L.; Moyses, H.E.; Calder, P.C.; Byrne, C.D. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the *WELCOME study. Hepatology 2014, doi:10.1002/hep.27289.
54. Nobili, V.; Alisi, A.; Della Corte, C.; Risé, P.; Galli, C.; Agostoni, C.; Bedogni, G. Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 1066-1070.
55. St-Jules, D.E.; Watters, C.A.; Brunt, E.M.; Wilkens, L.R.; Novotny, R.; Belt, P.; Lavine, J.E. Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 2013, 57, 627-633.
56. Cani, P.D.; Possemiers, S.; van de Wiele, T.; Guiot, Y.; Everard, A.; Rottier, O.; Geurts, L.; Naslain, D.; Neyrinck, A.; Lambert, D.M., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58, 1091-1103.
57. Fukuda, M.; Komiyama, Y.; Mitsuyama, K.; Andoh, A.; Aoyama, T.; Matsumoto, Y.; Kanauchi, O. Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. J. Clin. Biochem. Nutr. 2011, 49, 57-61.
58. Salminen, S.; Salminen, E. Lactulose, lactic acid bacteria, intestinal microecology and mucosal protection. Scand. J. Gastroenterol. Suppl. 1997, 222, 45-48.
59. Fan, J.G.; Xu, Z.J.; Wang, G.L. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World. J. Gastroenterol. 2005, 11, 5053-5056.
60. Holscher, H.D.; Faust, K.L.; Czerkies, L.A.; Litov, R.; Ziegler, E.E.; Lessin, H.; Hatch, T.; Sun, S.; Tappenden, K.A. Effects of prebiotic-containing infant formula on gastrointestinal tolerance and fecal microbiota in a randomized controlled trial. JPEN J. Parenter. Enteral. Nutr. 2012, 36, 95S-105S.
61. Daubioul, C.A.; Horsmans, Y.; Lambert, P.; Danse, E.; Delzenne, N.M. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: Results of a pilot study. Eur. J. Clin. Nutr. 2005, 59, 723-726.
62. Li, Z.; Yang, S.; Lin, H.; Huang, J.; Watkins, P.A.; Moser, A.B.; Desimone, C.; Song, X.Y.; Diehl, A.M. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37, 343-350.
63. Velayudham, A.; Dolganiuc, A.; Ellis, M.; Petrasek, J.; Kodys, K.; Mandrekar, P.; Szabo, G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009, 49, 989-997.
64. Xu, R.Y.; Wan, Y.P.; Fang, Q.Y.; Lu, W.; Cai, W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J. Clin. Biochem. Nutr. 2012, 50, 72-77.
65. Karahan, N.; Işler, M.; Koyu, A.; Karahan, A.G.; Başyığıt Kiliç, G.; Cırış, I.M.; Sütçü, R.; Onaran, I.; Cam, H.; Keskın, M. Effects of probiotics on methionine choline deficient diet-induced steatohepatitis in rats. Turk. J. Gastroenterol. 2012, 23, 110-121.
66. Mencarelli, A.; Cipriani, S.; Renga, B.; Bruno, A.; D’Amore, C.; Distrutti, E.; Fiorucci, S. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 2012, 7, doi:10.1371/journal.pone.0045425.
67. Aller, R.; de Luis, D.A.; Izaola, O.; Conde, R.; Gonzalez Sagrado, M.; Primo, D.; de La Fuente, B.; Gonzalez, J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2011, 15, 1090-1095.
68. Alisi, A.; Bedogni, G.; Baviera, G.; Giorgio, V.; Porro, E.; Paris, C.; Giammaria, P.; Reali, L.; Anania, F.; Nobili, V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39, 1276-1285.